Nuo Therapeutics, Inc.

Revenue more than doubled to $3.3M from the Smith+Nephew Distribution Agreement, driving gross profit growth to $2.2M, but gross margin compression from low-margin private label centrifuge sales and ongoing operating losses widened the net loss amid persistent cash burn.

Revenue breakdown: Product (57.3%), Aurix And Private Label Kits (35.8%), Aurix And Private Label Centrifuge Devices (4%).